Vertex Pharmaceuticals ($VRTX) reports positive results from two trials

Vertex Pharmaceuticals ($VRTX) stock jumped over 22 percent in its current trading session as it also created a new 52 weeks high of $111.88. The stock responded to the company’s announcement that it has received positive results  from two Phase 3 clinical trials assessing the combination of tezacaftor and ivacaftor [...]

By |March 29th, 2017|Opinions|0 Comments

Verastem ($VSTM) creates new 52 weeks high

Verastem Inc. ($VSTM) recently announced its fourth quarter and full year results. The company’s net loss for the year ended December 31, 2016 (2016 Period) was $36.4 million, or $0.99 per share, as compared to a net loss of $57.9 million, or $1.61 per share, for the year ended December 31, 2015. Verastem [...]

By |March 28th, 2017|Opinions|0 Comments

Idera Pharmaceuticals ($IDRA) continues upward trajectory

Idera Pharmaceuticals Inc. ($IDRA) recently reported that its fourth quarter net income stood at $822,000. The company had suffered a loss for the corresponding period of the previous year. Its net income per share basis was reported at $0.01. Idera earned $15.3 million in revenue during the said time period. [...]

By |March 27th, 2017|Opinions|0 Comments

Threshold Pharmaceuticals Inc. ($THLD) to merge with Molecular Templates

Threshold Pharmaceuticals Inc. ($THLD) recently announced that it has agreed to merge with cancer-focused biopharmaceutical company Molecular Templates Inc. in an all-stock deal.  Under the terms of the deal, the current shareholders of Molecular Templates will own nearly 65.6% of the newly formed combined entity. The remaining 34.4% will be [...]

By |March 24th, 2017|Opinions|0 Comments

Idera Pharmaceuticals reports Quarterly and full year results

Idera Pharmaceuticals Inc. ($IDRA) recently announced its fourth quarter financial results. The company’s quarterly net income stood at $822,000. On per share basis, it earned $0.01. Idera had suffered net loss in the corresponding quarter of the previous year. Its revenue for the quarter stood at $15.3 million. For the [...]

By |March 23rd, 2017|Opinions|0 Comments

Pain Therapeutics Inc. ($PTIE) reports positive FDA feedback for REMOXY ER

Pain Therapeutics Inc. ($PTIE) stock jumped over 55 percent in the pre-market session for Tuesday as the company announced receiving the FDA feedback regarding  the additional studies needed to refile its New Drug Application seeking approval of abuse-deterrent REMOXY ER (extended-release oxycodone capsules CII). The update followed a meeting between [...]

By |March 22nd, 2017|Opinions|0 Comments

Array BioPharma ($ARRY) withdraws NDA for US approval

Array BioPharma ($ARRY) announced that it has withdrawn its New Drug Application (NDA) in the U.S. seeking approval of binimetinib for the treatment of NRAS mutation-positive melanoma, a rare subtype of skin cancer. The company took the decision upon receiving feedback from the FDA that concluded that data from the [...]

By |March 21st, 2017|Opinions|0 Comments

Protalix BioTherapeutics ($PLX) Announces Financial Results

Protalix BioTherapeutics Inc. ($PLX) reported update and financial results for 2016. During the year, the company announced positive six and twelve-month interim phase II data in March 2016 and final results of the trial in August 2016 for Pegunigalsidase alfa (PRX-102) for Fabry Disease. In october 2016, it enrolled the first [...]

By |March 20th, 2017|Opinions|0 Comments

Omeros Corporation ($OMER) reports quarterly and annual results

Omeros Corporation ($OMER) reported its financial results for the fourth quarter and for the full year. The company’s revenue for the quarter stood at 412.9 million, up 94 percent on year over year basis. Its full year revenue was reported at $41.6 million, jumping 208 percent over the revenue for [...]

By |March 17th, 2017|Opinions|0 Comments

Catalyst Pharmaceuticals ($CPRX) announces results, inks new deal

Catalyst Pharmaceuticals ($CPRX) reported its fourth quarter and full year results. The company incurred a GAAP net loss of $18.07 million or $0.22 per basic and diluted share, compared to a GAAP net loss of $20.23 million or $0.25 per basic and diluted share, for the 2015 fiscal year.  For [...]

By |March 16th, 2017|Opinions|0 Comments

Arena Pharmaceuticals ($ARNA) Reports Q4 and Full Year Results

[...]

By |March 15th, 2017|Opinions|0 Comments

Peregrine Pharmaceuticals ($PPHM) reports Q3 Results

Peregrine Pharmaceuticals Inc. ($PPHM) provides updates for its operations and financial results for the third quarter of the year. The company announced that its three clinical trials under the collaboration with the NCCN are advancing as planned. It also plans to continue the comprehensive biomarker analysis of data collected in [...]

By |March 14th, 2017|Opinions|0 Comments

Vericel ($VCEL) reports fourth quarter results

Vericel Corporation ($VCEL) announced its fourth quarter and full year financial results. The company reported that its total net revenues for the quarter ended December 31, 2016 were approximately $16.5 million, consisting of $12.7 million of Carticel® net revenue and $3.8 million of Epicel® net revenues. Its total net revenues [...]

By |March 13th, 2017|Opinions|0 Comments

Immunomedics deal with Seattle Genetics is put on hold

Immunomedics Inc. ($IMMU) is reported to have halted its deal with Seattle Genetics, which was announced on February 10th earlier this year. However, the collaboration was criticized by the activist firm venBio for providing little value to the Immunomedics shareholders. VenBio is the largest shareholder Immunomedics with 9.9 percent stake. Four [...]

By |March 10th, 2017|Opinions|0 Comments

Medigus completes MUSE procedure in China

Medigus Ltd. ($MDGS) announced that it has completed its first MUSE procedure in China.  the procedure was reported successful, with the patient encountering minimal discomfort during the procedure. The patient has since been released from the hospital, with no procedural complications.  Chris Rowland, CEO of Medigus said, “With the completion [...]

By |March 9th, 2017|Opinions|0 Comments

Mesoblast receives Fast Track Designation for Cell Therapy

Mesoblast Limited ($MESO) reported that the United States Food and Drug Administration (FDA) has granted a Fast Track designation for the use of its cell therapy, MSC-100-IV. The treatment is designed to achieve improved overall response rate in children with steroid refractory acute Graft Versus Host Disease (aGVHD). The designation [...]

By |March 8th, 2017|Opinions|0 Comments

GlaxoSmithKline ($GSK) reports positive results from Nucala trial

GlaxoSmithKline plc ($GSK) announced data for its Nucala trial. The company said that patients with severe asthma, whose disease is driven by eosinophilic inflammation, treated with first-in-class biologic Nucala® (mepolizumab) added-on to standard of care, achieved clinically and statistically significant improvements in their health-related quality of life and lung function, in [...]

By |March 7th, 2017|Opinions|0 Comments

Ionis Pharmaceuticals reports positive trial results

Ionis Pharmaceuticals ($IONS) announced that the pivotal Phase 3 APPROACH study of volanesorsen met its primary endpoint of reducing triglyceride levels in patients with familial chylomicronemia syndrome. The trial was being carried out by the company’s wholly owned subsidiary Akcea Therapeutics. The average incoming triglyceride level of patients in the [...]

By |March 6th, 2017|Opinions|0 Comments

Amgen reports positive results for leukemia drug

Amgen Inc. ($AMGN) reported the results of the Phase 3 study of its leukemia drug Blincyto (blinatumomab). The company said that the drug almost doubled the overall survival (OS) rate in high-risk patients with B-Cell precursor acute lymphoblastic leukemia compared to chemotherapy. The data indicated that Blincyto resulted in a [...]

By |March 3rd, 2017|Opinions|0 Comments

Exact Sciences reports positive results from lung cancer test study

Exact Sciences Corporation ($EXAS) reported that its collaboration with Mayo Clinics for developing a blood-based lung cancer test shows promising prospects. The study involved nearly 400 patients, which demonstrated high accuracy for detecting lung cancer at all stages. Kevin Conroy, chairman and CEO of Exact Sciences, said "Our collaboration with [...]

By |March 2nd, 2017|Opinions|0 Comments
s2Member®